Fresh analysis indicates that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end traditional diet and exercise programs.
Research printed in a major medical journal demonstrates that while overweight individuals can lose about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users buying these drugs should be informed of the potential of fast weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass within about one and a half years.
Analyzing Treatments
The research, which reviewed 37 of trials involving thousands of participants, compared the results of these new drugs with conventional dieting.
The team note that people who lose weight through lifestyle changes alone typically have a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Doctors believe the mechanism of the injections accounts for the heightened rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication means appetite is no longer kept in check, making overeating much more probable."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of weight regain, the therapy should be considered long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "emphasize the persistent nature of obesity," comparing it to managing conditions like diabetes.
User Testimonies
Users who have stopped the jabs describe a powerful resurgence of hunger.
"It felt as if a trigger activating and you become ravenous," recalled an individual.
The struggle is worsened if users have not developed lasting lifestyle or habit modifications during therapy.
Widespread Use
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is more common among females than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while the jabs are powerful tools for shedding pounds, they are not a permanent fix and long-term success hinges on integrated behavioural changes.